Elzarkaa, Alaa A. and Sabaa, Bassma El and Abdelkhalik, Doaa and Mansour, Hassan and Melis, Mahmoud and Shaalan, Waleed and Farouk, Mohamed and Malik, Eduard and Soliman, Amr A. (2016) Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study. Journal of cancer research and clinical oncology, 142 (5). pp. 949-958. ISSN 0171-5216


Volltext (81Kb)
Official URL: http://dx.doi.org/10.1007/s00432-016-2116-5


PURPOSE: Cluster of differentiation (CD) 44 is a cell surface receptor that correlates with the development of drug resistance in epithelial ovarian cancer (EOC). Here, we prospectively investigated the clinical impact of CD44 expression on the development of chemoresistance, and on disease-free and overall survival in EOC. METHODS: This study included patients with primary serous EOC that was at International Federation of Gynecology and Obstetrics stages IIIB-IVA and tumors that were CD44 positive and negative in a 1:1 ratio. All patients underwent primary surgical cytoreduction, followed by six cycles of combined paclitaxel and carboplatin chemotherapy every 3 weeks. The treatment was considered complete after the chemotherapy had finished. All patients were followed up for 24 months after completing their chemotherapy. RESULTS: Of the 96 patients with serous EOC at stages IIIB-IVA, 51 % of the tumors were negative for the expression of CD44 and 49 % showed variable CD44 expression. Patients who had CD44-positive tumors had statistically significant shorter disease-free (p ≤ 0.001) and overall survival (p ≤ 0.001) intervals compared with patients with CD44-negative tumors. The hazard ratio for death was 6.8 (95 % confidence interval 2.4-19.2, p ≤ 0.001) among the patients with CD44-positive tumors. A multivariate analysis showed that carboplatin-resistant or carboplatin-refractory EOC was the only independent predictive factor for death. CONCLUSIONS: CD44 expression contributes to the development of carboplatin resistance in advanced serous EOC, and it may contribute to worse prognoses for patients, but it is neither an independent predictor of survival nor of recurrence.

Item Type: Article
Divisions: Faculty of Medicine and Health Sciences > Department of Human Medicine
Date Deposited: 09 Mar 2018 09:52
Last Modified: 09 Mar 2018 09:52
URI: https://oops.uni-oldenburg.de/id/eprint/3531
URN: urn:nbn:de:gbv:715-oops-36127
DOI: 10.1007/s00432-016-2116-5

Actions (login required)

View Item View Item

Document Downloads

More statistics for this item...